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We thank Dr. Pallet and Dr. Anglicheau for their interest in
our recent publication reporting autophagy in cisplatin
nephrotoxicity and its cytoprotective role.1 We are pleased
to learn that their latest work has also demonstrated
autophagy as a protective mechanism against cyclosporine
toxicity in renal cells and tissues.2 Interestingly, whereas
we showed the regulation of cisplatin-induced autophagy
by p53, BcL-2, and related mechanisms, Pallet et al. further
emphasized the involvement of ER stress in autophagy
during cyclosporine toxicity. Although we did not examine
ER stress in the cisplatin model, we believe this is a
possibility that deserves consideration and further inves-
tigation. As correctly pointed out, cisplatin can induce ER
stress. In this regard, Liu and Baliga3 showed evidence for
ER stress during cisplatin treatment of renal tubular cells.
Nevertheless, multiple stresses and signaling pathways are
induced or activated during cisplatin nephrotoxicity.4
Notably, cisplatin induces pathological alterations in
several subcellular sites or organelles including mitochon-
dria, ER, and the nucleus. As a result, cellular responses,
either cytoprotective or injurious, may be mediated by
multiple rather than a single mechanism.4 Certainly, a
specific stress or pathway may have a major role in the
induction of autophagy; whether it is ER stress remains to
be determined. In addition, the signaling pathways
activated by cisplatin may also cross talk and be integrated,
resulting in an impressive renal pathology. The recent
studies by this and other laboratories have suggested that
autophagy is a renoprotective mechanism during cisplatin
and cyclosporine nephrotoxicity.1,2,5 However, whether
this conclusion can be generalized to other kidney injury
models (for example renal ischemia-reperfusion) remains
to be investigated, as excessive autophagy can lead to cell
death. Thus we have to agree with Dr. Lieberthal that ‘the
extent to which autophagy can ameliorate kidney injury
caused by other types of renal insults remains to be
determined’.6 It is hoped that these studies have provided
impetus for investigation of autophagy in renal patho-
physiology.
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Telmisartan is more effective than
losartan in reducing proteinuria
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To the Editor: We read with interest the paper that
Telmisartan is more effective than losartan in reducing
proteinuria in patients with Diabetic Nephropathy recently
published in Kidney International by Bakris et al.1 where the
effects of telmisartan 80 mg was compared with losartan
100 mg in 860 patients with type 2 diabetes treated for 52
weeks. The authors showed that with telmisartan, proteinuria
decreased from 1.42 to 0.95 g per g creatinine (Po0.0001)
and with losartan, proteinuria decreased from 1.39 to 1.05 g
per g creatinine (Po0.0001) at the end of the study. They
also documented a trend in favor of telmisartan where there
was a difference of 4.2 mm Hg difference in systolic blood
pressure compared to losartan. We would like to comment on
the dose of telmisartan and losartan used in Bakri’s study.
From our observation, comparing telmisartan 80 mg with
losartan 100 mg would favor telmisartan with regards to
clinical efficacy in particular with respect to reduction of
proteinuria.
We would like to share our own experience in a clinical
trial involving patients with IgA nephritis treated with
losartan 100 mg (n¼ 45) compared to those treated with
losartan 200 mg (n¼ 61) over a 6-year period from 2001 to
2007.2 In the losartan 100 mg group, proteinuria decreased
from 2.1±1.0 to 1.7±1.0 g/day compared to losartan 200 mg
group where proteinuria decreased from 2.1±0.8 to
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